Details

Autor(en) / Beteiligte

• Gordon, Anthony C
• Perkins, Gavin D
• Singer, Mervyn
• McAuley, Daniel F
• Orme, Robert M.L
• Santhakumaran, Shalini
• Mason, Alexina J
• Cross, Mary
• Al-Beidh, Farah
• Best-Lane, Janis
• Brealey, David
• Nutt, Christopher L
• McNamee, James J
• Reschreiter, Henrik
• Breen, Andrew
• Liu, Kathleen D
• Ashby, Deborah

Titel

Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis

Ist Teil von

• The New England journal of medicine, 2016-10, Vol.375 (17), p.1638-1648

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• In a randomized trial, over 500 patients with sepsis received levosimendan or placebo in addition to usual care. Levosimendan did not result in a lower likelihood of organ dysfunction or lower mortality. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection 1 and is a leading cause of death worldwide. Septic shock is the most severe form of the condition and results in circulatory and metabolic abnormalities. 2 Persisting hypotension despite adequate fluid resuscitation is due to a combination of profound vasodilatation, vascular hyporeactivity to catecholamines, and myocardial depression. 3 Although catecholamines are the recommended first-line therapy for septic shock, 4 high doses of administered catecholamines and high levels of circulating catecholamines are associated with poor outcomes and severe side effects, including myocardial injury and peripheral ischemia. 5 – 7 Levosimendan is . . .